Research suggests that Echinacea, particularly Echinacea purpurea, may support cold and flu symptom relief through multiple mechanisms, including direct antiviral activity against common respiratory viruses such as rhinovirus and influenza, as well as suppression of pro-inflammatory cytokines like IL-6 and IL-8 that drive many respiratory symptoms. Studies indicate that specific compounds within the plant, particularly certain alkylamides, may account for much of this activity, and preliminary cell-culture research has also examined potential effects against SARS-CoV-2, though the authors of that study emphasize clinical trials would be needed before drawing any practical conclusions. The available evidence reviewed here consists entirely of laboratory and cell-culture studies rather than randomized controlled trials or meta-analyses in human populations, which limits how directly these findings translate to real-world use. Additionally, one case report raises a caution about a potential interaction between Echinacea and certain chemotherapy drugs, underscoring that while the mechanistic research is promising, the full picture of Echinacea's effects and safety in humans remains an open area of study.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Effects of Echinacea purpurea and Alkylamides on Respiratory Virus Replicatio... | Other | 2025 | Supports | 100 |
| Probable etoposide interaction with Echinacea. | Other | 2012 | Neutral | 95 |
| Induction of multiple pro-inflammatory cytokines by respiratory viruses and r... | Other | 2009 | Supports | 90 |
| <i>In vitro</i>screening of anti-viral and virucidal effects against SARS-CoV... | Other | 2021 | Supports | 85 |